A strong foundation for accelerated growth

Time is of the essence. As antibiotic resistance threatens to overwhelm the successful treatment of infection, the introduction of new drugs becomes critical.

MiddleBrook^™ is developing a superior portfolio of new antibiotic and anti-infective products. Thanks to our novel pulsatile dosing discovery, each product in the MiddleBrook portfolio promises to offer at least one significant advantage over similar drugs currently on the market. Our commercialization efforts should be strengthened by the benefits of efficiency, effectiveness, and convenience our products will offer.

• Once-a-day formulation
• Lower dosages
• Shorter duration of therapy
• Reduced side effects profile
• Reduced incidence of resistance
• Combination products with superior efficacy over either product alone
• Improved pediatric dosage form
• Improved geriatric dosage form